Hypochlorous Acid-Activated UCNPs-LMB/VQIVYK Multifunctional Nanosystem for Alzheimer's Disease Treatment

• Published in: Journal of functional biomaterials Vol. 14; no. 4; p. 207
• Main Authors: Qiao, Luying, Shen, Yang, Li, Guangzhi, Lv, Guanglei, Li, Chunxia
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.04.2023; MDPI
• Subjects: Advertising executives; Agglomeration; Alzheimer's disease; amyloid-β; Biocompatibility; Chromatography; Cytotoxicity; Depolymerization; Hypochlorous acid; Luminescence; Medical treatment; Nanomaterials; Nanoparticles; Neurodegenerative diseases; Neurotoxicity; Optical properties; Peptides; Proteins; reactive oxygen species; Singlet oxygen; Sodium; Tau protein; Toxicity; Upconversion; β-Amyloid; amyloid-β; upconversion; Alzheimer’s disease; Tau protein; reactive oxygen species
• ISSN: 2079-4983; 2079-4983
• DOI: 10.3390/jfb14040207

The development of nanosystems, which can photooxygenate amyloid-β (Aβ), detect the Tau protein, and inhibit effectively the Tau aggregation, is increasingly important in the diagnosis and therapy of Alzheimer's disease (AD). Herein, UCNPs-LMB/VQIVYK (UCNPs: upconversion nanoparticles, LMB: Leucomethylene blue, and VQIVYK: Biocompatible peptide) is designed as a HOCl-controlled released nanosystem for AD synergistic treatment. Under exposure to high levels of HOCl, the released MB from UCNPs-LMB/VQIVYK will produce singlet oxygen ( O ) under red light to depolymerize Aβ aggregation and reduce cytotoxicity. Meanwhile, UCNPs-LMB/VQIVYK can act as an inhibitor to decrease Tau-induced neurotoxicity. Besides, UCNPs-LMB/VQIVYK can be used for upconversion luminescence (UCL) due to its unexceptionable luminescence properties. This HOCl-responsive nanosystem offers a new therapy for AD treatment.